TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pediatric Laser Acupuncture and Renal Biopsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* older than 6 years old~* admitted for a transplant or native kidney biopsy performed by pediatric nephrology~Exclusion Criteria:~* Prisoners~* Pregnant females~* Those who are unable to participate with the visual analog scale

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Aculaser applied to sham points (Type: SHAM_COMPARATOR): The patient will receive aculaser, performed by licensed acupuncturist, to sham acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
- Aculaser applied to kidney points (Type: EXPERIMENTAL): The patient will receive aculaser, performed by licensed acupuncturist, to known kidney acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed stage III or IV melanoma gp100 positive tumor cells and/or tyrosinase positive tumor cells HLA type A1, A2, or A3 Measurable disease May have up to 3 brain metastases if all are less than 2 cm in diameter and are asymptomatic, and there is no mass effect or they have been treated successfully by surgical excision or by gamma knife radiation therapy~PATIENT CHARACTERISTICS: Age: 18 to 79 Performance status: ECOG 0-1 Life expectancy: Not specified Hematopoietic: Absolute neutrophil count greater than 1,000/mm3 Platelet count greater than 100,000/mm3 Hemoglobin greater than 9 g/dL Hepatic: Bilirubin no greater than 2.5 times upper limit of normal (ULN) AST and ALT no greater than 2.5 times ULN Alkaline phosphatase no greater than 2.5 times ULN Renal: Creatinine no greater than 1.5 times ULN Cardiovascular: No New York Heart Association class II, III, or IV heart disease Other: No known or suspected allergy to any component of the vaccine No medical condition that would preclude study Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY: Biologic therapy: At least 3 months since prior growth factors At least 3 months since prior agents with putative immunomodulating activity (except nonsteroidal antiinflammatory agents) At least 1 year since other prior melanoma vaccinations Chemotherapy: At least 3 months since prior chemotherapy No concurrent chemotherapy Endocrine therapy: At least 3 months since prior corticosteroids No concurrent corticosteroids Radiotherapy: At least 3 months since prior radiotherapy No concurrent radiotherapy Surgery: See Disease Characteristics Other: At least 3 months since other prior investigational drugs or therapy At least 3 months since prior allergy desensitization injections At least 14 days since completion of acute treatment for a serious infection No concurrent allergy desensitization injections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Peptides pulsed on dendritic cells (Type: EXPERIMENTAL): 4 melanoma peptides pulsed on monocyte-derived dendritic cells
- Peptides in GMCSF-in-adjuvant (Type: EXPERIMENTAL): 4 melanoma peptides administered as an emulsion with GM-CSF and Montanide ISA-51 adjuvant.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Microdialysis and Pharmacokinetic Study of TR-701

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Body mass index of 20 to 29 kg/m2~* Agree not to consume any products containing tobacco, alcohol, quinine, grapefruit, caffeine, or high levels of tyramine~* Agree not to use any other medication~* Female subjects must be postmenopausal (for at least 6 months), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control~Exclusion Criteria:~* History of gastric or duodenal ulcer within 1 year before enrollment~* Has known or suspected hypersensitivity or intolerance to heparin, if an indwelling cannula (e.g., heparin lock) is used~* Recent febrile illness (less than 72 hours before the first intake of study medication).~* Significant blood loss (300 mL) or donation of blood within the 60 days before the Screening visit~* Women who are pregnant or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Pilot study (Type: EXPERIMENTAL): 3 subjects, open lable, microdialysis single dose.
- Main Study (Type: EXPERIMENTAL): 12 subjects, open label, single dose of 600 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective, Non-interventional, Multi-center Safety Study of Mirena for Heavy Menstrual Bleeding and Dysmenorrhea

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Female patients diagnosed with HMB or/and dysmenorrhea.~* Patients for whom newly starting treatment with Mirena was made as per investigator's routine treatment practice~* Written informed consent~Exclusion Criteria:~* Patient whose purpose is only contraception

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mirena (Type: None): Mirena treatment group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* 3 or more episodes of acute VVC in the past 12 months~* Positive KOH or Gram stain~* Total vulvovaginal signs and symptoms score of ≥3 at screening visit~* Total vulvovaginal signs and symptoms score of \<3 at baseline visit~* Must be able to swallow pills~Key Exclusion Criteria:~* Presence or a history of another vaginal or vulvar condition(s)~* Evidence of major organ system disease~* History of cervical cancer~* Poorly controlled diabetes mellitus~* Pregnant~* Recent use of topical or systemic antifungal or antibacterial drugs~* Recent use of immunosuppressive or systemic corticosteroid therapies

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oteseconazole (VT-1161) 150mg capsule (Type: EXPERIMENTAL): Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
- Placebo capsule (Type: PLACEBO_COMPARATOR): Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or non-pregnant female participants aged ≥ 6 calendar months to \< 18 years at the time of the first study vaccination.~* For participants aged ≥ 6 months to \< 9 years, born after a normal gestation period (between 36 and 42 weeks).~* Females of childbearing potential (i.e., ovulating, pre-menopausal, not surgically sterile) must be abstinent or be willing to use a medically accepted contraceptive regimen for at least 2 months after vaccination. Females aged ≥ 9 years must also return a negative urine pregnancy test at enrollment.~Exclusion Criteria:~* Known hypersensitivity to a previous dose of influenza vaccine or allergy to eggs, chicken protein, neomycin, polymyxin, or any components of the Study Vaccine.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Afluria Cohort A (Type: EXPERIMENTAL): Age 6 months to \< 3 years
- Afluria Cohort B (Type: EXPERIMENTAL): Age 3 to \< 9 years
- Afluria Cohort C (Type: EXPERIMENTAL): Age 9 to \< 18 years
- Fluzone Cohort A (Type: ACTIVE_COMPARATOR): Age 6 months to \< 3 years
- Fluzone Cohort B (Type: ACTIVE_COMPARATOR): Age 3 to \< 9 years
- Fluzone Cohort C (Type: ACTIVE_COMPARATOR): Age 9 to \< 18 years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sertraline Effect in Uremic Pruritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ≥1 month of maintenance haemodialysis, 3 times per week for 4 hours.~2. Adult patients with ages between 18-80 years.~Exclusion Criteria:~1. Primary skin diseases (eczema, psoriasis, allergic dermatitis or drug rash).~2. Peripheral neuropathy, thyroid disease, leukemia, lymphoma, liver disease, Systemic lupus erythematosus or pregnancy.~3. Patients who consumed emollients cream, antihistamine, opioid antagonist, immunosuppressants, cholestyramine, corticosteroids or UVB phototherapy 1 month before study.~4. calcium X phosphorus (Ca X P) \>55.0 mg/dl, P \>5.5 mg/dl, parathyroid hormone (PTH) \>450 pg/ml.~5. Selective serotonin reuptake inhibitors intolerance.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- sertraline (Type: EXPERIMENTAL): they will receive sertraline at the intended dose of 50 mg twice daily for 8 weeks.
- placebo (Type: PLACEBO_COMPARATOR): They will receive a placebo in the form of multivitamin tablets similar to the experimental drug with the same regimen, as one tablet /day for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) (LAR) can and will comply with the requirements of the protocol.~* Children, male or female, aged between 3 and 17 years at the time of the first study vaccination.~* Written informed consent obtained from the subject parent(s) or LAR(s) of the subject. Assent obtained from the subject when applicable.~* Healthy children as established by medical history and clinical examination when entering into the study.~* Parent/LAR with access to a consistent means of telephone contact, land line or mobile, but NOT a pay phone or other multiple-user.~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of the study vaccine or planned use during the study period.~* Clinically or virologically confirmed influenza infection within six months preceding the study start.~* Planned administration of any vaccine 30 days prior and 30 days after any study vaccine administration.~* Chronic administration of immunosuppressants or other immune-modifying drugs within three months prior to enrolment in this study or planned administration during the study period.~* Acute disease and/or fever at the time of enrolment~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.~* Acute or chronic, clinically-significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history and physical examination.~* Previous administration of any H1N1 A/California-like vaccine.~* Administration of immunoglobulins and/or any blood products within the three months prior to the enrolment in this study, or planned during the study.~* If the subject is female and if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for two months after completion of the vaccination series.~* Any known or suspected allergy to any constituent of influenza vaccines;a history of anaphylactic-type reaction to any constituent of influenza vaccines; or a history of severe adverse reaction to a previous influenza vaccine.~* Known use of an analgesic or antipyretic medication within 12 hours prior to first vaccination.~* Child in Care.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with NPC in first or subsequent relapse or with primary refractory disease or high risk (T3 or T4, or node positive disease) in whom the EBV genome or antigens have been demonstrated in tissue biopsies will be eligible for this trial. -Patients with a life expectancy \>6 weeks~* Patients with a Karnofsky score of \>/= 50~* No severe intercurrent infection.~* Patient, parent/guardian able to give informed consent.~* Patients with bilirubin \<2x normal, SGOT \<3x normal, and Hgb \>8.0~* Patients with a creatinine \<2x normal for age~* Patients should have been off other investigational therapy for one month prior to entry in this study.~Exclusion Criteria:~-Patients with a life expectancy of \<6 weeks. -Patients with a Karnofsky score of \< 50. -Patients with a severe intercurrent infection. -Patient, parent/guardian unable to give informed consent. -Patients with a bilirubin \>2x normal. SGOT \>3x normal or abnormal prothrombin time. -Patients with a creatinine \>2x normal for age -Due to unknown effects of this therapy on a fetus, pregnant women are excluded from this research. The male partner should use a condom.~Note: Patients who would be excluded from the protocol strictly for laboratory abnormalities can be included at the investigators discretion after approval by the CAGT Protocol Review Committee and the FDA reviewer.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EBV specific CTL (Type: EXPERIMENTAL): autologous EBV specific CTLs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary insomnia~* Participant is able to read, understand, and complete questionnaires and diaries~* If female, participant and partner both agree to use acceptable contraception. If male partner does not use an effective form of contraception, female participant must use 2 acceptable forms of contraception~* If ≥65 years of age, score of ≥25 on the Mini Mental State Examination (MMSE)~Exclusion Criteria:~* If female, participant is pregnant~* Participant expects to donate eggs or sperm during the study~* Recent and/or active history of a confounding neurological disorder~* History of clinically unstable cardiovascular disorder within the last 6 months~* Lifetime history of bipolar disorder~* Psychiatric condition that requires treatment with a medication prohibited by the study, or any other psychiatric condition that would interfere with the participant's ability to participate in the study~* History of substance abuse/dependence~* History of cancer ≤5 years prior to study participation except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer~* Evidence of suicidality (based on a score of 2 on the Quick Inventory of Depressive Symptomatology Self-Report 16-Item (\[QIDS-SR16\] suicide item #12)~* Participant has travelled across \>3 time zones or \>3 hour time difference in the last 2 weeks~* History of permanent night shift work or rotating day/night shift work in the past 2 weeks~* Body Mass Index (BMI) \>40 kg/m\^2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Suvorexant (Type: EXPERIMENTAL): After a 1-week single-blind placebo run-in, participants received suvorexant (40 mg for participants aged 18 to \<65 years; and 30 mg for participants aged ≥65 years) daily before bedtime for 12 months during the Treatment Phase.
- Placebo (Type: PLACEBO_COMPARATOR): After a 1-week single-blind placebo run-in, participants received dose-matched placebo to suvorexant (administered according to age) daily before bedtime for 12 months during the Treatment Phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Quality Improvement Project on Impacted Fetal Head at Cesarean Section

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patient: The patient study population includes all patients age 18-45 who underwent cesarean section during the second stage of labor (during the time period July 2016-June 2019 at Regions Hospital and Methodist Hospital) and their infants. Second stage is defined as the time between complete cervical dilation and delivery of the infant.~Medical staff: All staff members (staff physicians, residents, nurses, surgical technicians) at Regions Hospital who practice in the Birth Center who underwent required simulation education regarding delivery of impacted fetal heads during second stage cesarean section and completed the surveys as part of the QI project. Note: Medical staff were not enrolled in the research study; rather, staff survey data from the QI project was a data source for the study.~Exclusion Criteria:~Patient: Exclusion criteria include patients who underwent cesarean section in second stage for malpresentations (i.e., breech and noncephalic presentations) and patients who underwent cesarean section prior to 37 weeks gestation.~Medical staff: No exclusion criteria

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Quality Improvement Project (Pre-Period) (Type: None): Quality Improvement Project: Pre-Period (7/1/2016 to 12/31/2017) Patients received care at the intervention hospital in the 18 months before providers participated in the department-wide, simulation-based educational training.
- No Quality Improvement Project (Pre-Period) (Type: None): No Quality Improvement Project: Pre-Period (7/1/2016 to 12/31/2017) Patients received care at the comparison hospital where no quality improvement educational training had occurred.
- Quality Improvement Project (Post-Period) (Type: None): Quality Improvement Project: Post-Period (1/1/2018 to 6/30/2019) Patients received care at the intervention hospital in the 18 months after providers participated in the department-wide, simulation-based educational training.
- No Quality Improvement Project (Post-Period) (Type: None): No Quality Improvement Project: Post-Period (1/1/2018 to 6/30/2019) Patients received care at the comparison hospital where no quality improvement educational training had occurred.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete